CD4 and myeloid sarcoma: Among MS patients treated with glucocorticoid, Aristimuño et al. (2008) found that the number of CD4+ and CD8+ regulatory T lymphocytes increased, while the number of CD8+ effector and memory T lymphocytes had a downward trend, indicating that CD8+ regulatory T lymphocytes may play a role in preventing the progression of MS, while CD8+ effector T lymphocytes promote the progression of MS.